Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, Li C, Cheng B, Xiong S, Li J, He J, Liang W.
Wang M, et al.
Cancer. 2021 Mar 1;127(5):777-786. doi: 10.1002/cncr.33270. Epub 2020 Oct 29.
Cancer. 2021.
PMID: 33119182
Free article.
Thus, this article assesses the rate of irAEs with a PD-(L)1 inhibitor plus chemotherapy (I+C) in comparison with a PD-(L)1 inhibitor alone (I) and evaluates the indirect relative risk (RR) with I+C versus I. The key finding is that in comparison with a PD-(L)1 inhibitor a …
Thus, this article assesses the rate of irAEs with a PD-(L)1 inhibitor plus chemotherapy (I+C) in comparison with a PD-(L)1 inhibitor alone …